- Author:
Dong Wook JEKARL
1
;
Jae Kwon KIM
;
Jay Ho HAN
;
Howon LEE
;
Jaeeun YOO
;
Jihyang LIM
;
Yonggoo KIM
Author Information
- Publication Type:REVIEW ARTICLE
- From:Blood Research 2023;58(S1):1-7
- CountryRepublic of Korea
- Language:English
- Abstract: Transfusion support for hematopoietic stem cell transplantation (HSCT) is an essential part of supportive care, and compatible blood should be transfused into recipients. As leukocyte antigen (HLA) matching is considered first and as the blood group does not impede HSCT, major, minor, bidirectional, and RhD incompatibilities occur that might hinder transfusion and cause adverse events. Leukocyte reduction in blood products is frequently used, and irradiation should be performed for blood products, except for plasma. To mitigate incompatibility and adverse events, local transfusion guidelines, hospital transfusion committees, and patient management should be considered.